연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2024년 | 2023년 | 2022년 | 2021년 | 2020년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 179편 | 173편 | 163편 | 184편 | 135편 |
| 공동 | 147편 | 120편 | 115편 | 136편 | 168편 | |
| 합계 | 326편 | 293편 | 278편 | 320편 | 303편 | |
2207. Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study.
Park H, Shin DY, Kim I, Sohn SK, Koh Y, Lee JH, Lee KH, Kim DY, Kim HJ, Ahn JS, Lee JO, Bang SM, Cheong JW, Park SG, Park S, Lee YJ, Ahn SY.
In Vivo. 2019 Nov-Dec;33(6):2273-2280.
Link
2206. Influence of Tumor Thrombus on Occurrence of Distant Venous Thromboembolism and Survival in Patients With Renal Cell Carcinoma After Surgery.
Park H, Jeong CW, Yuk H, Ku JH, Kim HH, Kwak C, Kim I.
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029618823288.
Link
2205. Strong association between herpes simplex virus-1 and chemotherapy-induced oral mucositis in patients with hematologic malignancies.
Hong J, Park HK, Park S, Lee A, Lee YH, Shin DY, Koh Y, Choi JY, Yoon SS, Choi Y, Kim I.
Korean J Intern Med. 2019 Sep 9.
Link
2204. High-Throughput Multiplex Immunohistochemical Imaging of the Tumor and Its Microenvironment.
Koh J1, Kwak Y1,2, Kim J3, Kim WH1,3,4.
Cancer Res Treat. 2019 May 27. doi: 10.4143/crt.2019.195. [Epub ahead of print]
Link
2203. Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma.
Lee JJ1, Park S2, Park H3, Kim S4, Lee J5, Lee J6, Youk J2, Yi K2, An Y3, Park IK7, Kang CH7, Chung DH4, Kim TM8, Jeon YK9, Hong D5, Park PJ10, Ju YS11, Kim YT12.
Cell. 2019 Jun 13;177(7):1842-1857.e21. doi: 10.1016/j.cell.2019.05.013. Epub 2019 May 30.
Link
2202. Impact of smoking on thyroid gland: dose-related effect of urinary cotinine levels on thyroid function and thyroid autoimmunity.
Kim SJ, Kim MJ, Yoon SG, Myong JP, Yu HW, Chai YJ, Choi JY, Lee KE.
Scientific reports. 2019 Mar 12;9(1):4213.
Link
2201. The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.
Heo JY1,2, Park C1, Keam B1,3, Ock CY1, Kim M1, Kim TM1,3, Kim DW1,3, Kim SH4, Kim YJ4, Lee JS4, Heo DS1,3.
Thorac Cancer. 2019 Nov;10(11):2117-2123. doi: 10.1111/1759-7714.13195. Epub 2019 Sep 11.
Link
2200. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
Kim YJ1, Keam B2, Ock CY3, Song S4, Kim M3, Kim SH1, Kim KH5, Kim JS5, Kim TM6, Kim DW6, Lee JS1, Heo DS6.
Lung Cancer. 2019 Oct;136:122-128. doi: 10.1016/j.lungcan.2019.08.031. Epub 2019 Aug 29.
Link
2199. First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Kim R1, Keam B2, Hahn S3, Ock CY1, Kim M1, Kim TM4, Kim DW4, Heo DS4.
Clin Lung Cancer. 2019 Sep;20(5):331-338.e4. doi: 10.1016/j.cllc.2019.05.009. Epub 2019 May 11.
Link
2198. Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients.
Yoo SH1, Keam B2,3, Ock CY1, Kim S4, Han B5, Kim JW6, Lee KW6, Jeon YK4, Jung KC4, Chung EJ7, Kwon SK7, Ahn SH7, Sung MW7, Heo DS1,8.
Sci Rep. 2019 May 22;9(1):7680. doi: 10.1038/s41598-019-44206-2.
Link